LM-108 Receives Fast Track Designations for Cancer Treatments from US FDA

April 21^st, 2023 - LaNova Medicines Ltd. announced that its new drug candidate LM-108 received Fast Track Designation from the FDA for the treatment of NSCLC in April 2023, marking significant progress in its development.

About CCR8:

CCR8 (chemokine receptor 8) is a member of the chemokine receptor subfamily under the G protein-coupled receptor (GPCR) family. Previous studies revealed that the expression of CCR8 is low in peripheral blood cells and normal tissues, but is specifically upregulated in tumor-infiltrating Tregs in multiple cancers including breast cancer, colorectal cancer, and lung cancer. Anit-CCR8 antibodies can selectively mediate the depletion of tumor-infiltrating Tregs, thereby enhancing the anti-tumor immune response and inhibiting tumor growth.